



155 boulevard Haussmann - 75008 Paris (France)
Phone + 33(0)1 45 64 44 60 - Fax +33(0)1 45 64 44 64
e-mail: fincom@cerep.fr - www.cerep.com



940 Winter Street - Waltham, MA 02451 (USA)
Phone: +1 (781) 663 6900 - Fax: +1 (781) 663 5985
www.perkinelmer.com

PerkinElmer and Cerep announce expansion of new kinase assay offerings to accelerate drug candidate screening and validation

Lille, France, April 28, 2009 - News release 2009/04

At the 15th Annual Society for Biomolecular Sciences (SBS) Conference today, PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, and Cerep SA, a leading provider of drug candidate screening and profiling technologies, announced the expansion of their kinase assay offering. Close to 200 new kinase assays validated with PerkinElmer's LANCE[®] Ultra[™] technology will be offered for use through Cerep's drug candidates selection and qualification services.

The collaboration between the two companies first announced in April 2008 delivers custom drug discovery services, through a combination of PerkinElmer's leading assay technologies, and Cerep's unique target screening and drug discovery offerings. Key therapeutic research pathways supported by the new 189 kinase assays include cancer, cardiac disease, central nervous system disorders, inflammation, diabetes, and metabolic disorders, amongst others.

"The extensive range of high quality kinase assays now available for screening and profiling through this collaboration is a compelling complement to the profiling services offered by Cerep. It provides our customers with the expansive range of products and expertise necessary for broad compound screening campaigns to aid their research," said Richard M. Eglen, PhD, president, Bio-discovery, PerkinElmer. *"Our clients can now benefit from testing their compounds against a broad range of kinase targets via a single platform, validated for performance with PerkinElmer's innovative LANCE Ultra portfolio and diversified Ulight[™] substrates, for consistently high quality results."*

"Cerep is delighted with the extension of our combined capabilities with PerkinElmer represented by this expansion of kinase offerings to our clients," said Thierry Jean, chairman and chief executive officer, Cerep SA. *"This initial success of our collaboration is validation that our combined model of assays and screening enables clients to avoid time consuming and costly in-house assay development by taking their compounds directly into high throughput screening and profiling against the desired drug targets."*

The collaboration with Cerep provides PerkinElmer customers with an option to work with a single vendor throughout the entire drug discovery process. Cerep customers in turn have access to several key assay development and detection platforms from PerkinElmer's Bio-discovery business, including AlphaScreen[®], AlphaLISA[®], LANCE[®], LANCE[®] Ultra[™] and radioligand binding assays for G protein-coupled receptor (GPCR) and kinase assay development ...

■ About Cerep

Focussing on *in vitro* pharmacology and ADME-Tox, Cerep [Nyse Euronext – CER] provides solutions allowing cost-effective drug discovery by identifying at early stages the most promising drug candidates and eliminating compounds likely to fail in development. Cerep's technologies benefit to more than 460 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms. Additional information is available through www.cerep.com.

Contact

Catherine Moreau, c.moreau@cerep.fr, tel. +33 1 45 64 44 65

■ About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately \$ 2 billion in 2008, has around 8,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or **1-877-PKI-NYSE**.

Contact

Mario Fante, mario.fante@perkinelmer.com, tel. +1 (781) 781 663 5602

Code ISIN FR0004042232
Euronext Paris
Euronext - Local securities

Cerep SA
155 boulevard Haussmann
75008 Paris
France
tel + 33(0)1 45 64 44 60
fax +33(0)1 45 64 44 64
e-mail: fincom@cerep.fr
www.cerep.com